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Distinct Roles for IL-1 Receptor Type I Signaling in
Early Versus Established Leishmania major Infections
Susanna Lopez Kostka1, Ju¨rgen Knop1, Abdo Konur2, Mark C. Udey3 and Esther von Stebut1
IL-1a/b released by infected dendritic cells (DC) plays a critical role in the development of protective immunity
against Leishmania major. Previous studies demonstrated that treatment of susceptible BALB/c mice with IL-1a
during T-cell priming (days 1–3 post-infection) induced T helper (Th)1-mediated protection. In contrast, we now
demonstrate that prolonged treatment with IL-1a (for 3 weeks) worsened disease outcome. To characterize the
receptor involved, L. major infections in IL-1 receptor type I (IL-1RI) knockout mice were studied. In C57BL/6
IL-1RI/ mice, the IL-1a-mediated protective effect was abrogated. The course of high-dose infection (2 105
parasites) in IL-1RI/ mice was not different from controls. Surprisingly, in low-dose infections (103 parasites),
IL-1RI/ mice developedB50% smaller lesions compared to wild types, decreased parasite loads and increased
IFNg/IL-4 ratios. Interestingly, naive Th0 and Th2, but not Th1, cells expressed IL-1RI ex vivo. We conclude that
IL-1RI mediates the effect of IL-1a in leishmaniasis in C57BL/6 mice. In addition, IL-1 appears to play distinct roles
in Th education and maintenance. In early phases of physiologically relevant, low-dose L. major infections, IL-1
facilitates Th1 development from Th0 cells, whereas later on IL-1RI signaling promotes Th2 expansion and
worsens disease outcome. Effects of IL-1 on disease outcome may be related to levels of IL-1RI on Th
subpopulations.
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INTRODUCTION
Control of Leishmania infections is ultimately dependent on
the IL-12-dependent production of Th1/T cell (Tc1)-derived
IFN-g that activates infected macrophages to eliminate
parasites (Reiner and Locksley, 1995; Sacks and Noben-
Trauth, 2002). Skin dendritic cells (DC) infected with
Leishmania major represent important sources of IL-12.
However, BALB/c mice develop Th2 immunity against
Leishmania and succumb to infection due to uncontrolled
parasite replication, even though L. major-infected BALB/c
DC produce IL-12 (von Stebut et al., 2000). We and others
have determined that factors intrinsic to DC are also
important for efficient Th1 education (Filippi et al., 2003;
von Stebut et al., 2003). DC derived from Leishmania-
susceptible BALB/c mice and genetically resistant B10.D2
mice preferentially induced Th2 and Th1 responses in CD4þ
T cells, respectively (Filippi et al., 2003). IL-1b released from
activated DC appeared to be responsible for this difference.
Independently, we found that L. major-infected DC from
BALB/c mice produced significantly less IL-1a than C57BL/6
DC, and treatment with IL-1a during T-cell priming resulted
in Th1 induction and protection from progressive disease
in otherwise Th2-prone BALB/c mice. Thus, differential
expression of IL-1 by DC may regulate development of
characteristic Th responses in various disease models
(Iwasaki, 2003).
The mechanism by which IL-1 influences Th differentia-
tion is controversial. Some studies suggested that IL-1 favors
the expansion of Th2, but not Th1 clones, by increasing their
responsiveness to IL-4 or by serving as a costimulatory signal
(Greenbaum et al., 1988; Huber et al., 1998; Lichtman et al.,
1988; Shibuya et al., 1998). Other data indicated that IL-1
was not required for Th2 differentiation (Seder and Paul,
1994). Strain dependence of IL-1 influences and requirements
was suggested by data indicating that spleen cell-derived
IL-1a and tumor necrosis factor-a together with IL-12 was
required to induce efficient Th1 priming in naive CD4þ
T cells from BALB/c mice transgenic for a T-cell receptor
(TCR)a/b recognizing ovalbumin whereas cells from C57BL/6
mice required only IL-12 (Shibuya et al., 1998).
The literature regarding the involvement of IL-1 in
regulation of T-cell responses to Leishmania is somewhat
confusing. In addition to studies of IL-1 production described
above (Filippi et al., 2003; von Stebut et al., 2003),
macrophages infected with L. major produced IL-1a only
when generated from Leishmania-resistant C3H/HeN or
C3H/HeJ mice but not from BALB/c mice (Delfino et al.,
1995; Bersudsky et al., 2000). In L. donovani infections,
administration of IL-1a to chronically infected mice resulted
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in enhanced IFN-g production, but not healing (Curry and
Kaye, 1992). Other studies suggested that treatment with IL-1
in L. major infections is detrimental and leads to enhanced
disease progression (Ajdary et al., 1997). Administration of an
IL-1RI mAb with the intention to prevent costimulation of Th2
cells significantly reduced lesion sizes (Theodos et al., 1994).
Cells (such as macrophages) from BALB/c mice produced
more IL-1a after infection with L. major compared to cells
from resistant strains, which in turn promoted the expansion
of Th2, but not Th1 cells in vitro (Chakkalath and Titus, 1994;
Soares et al., 1997).
These seemingly conflicting studies regarding the role of
IL-1a in Th education prompted us to study induction of Th-
dependent immunity in mice against L. major in some detail.
We first determined that IL-1a has beneficial or detrimental
effects on the course of infection of wild-type mice
depending on the time of administration. Using IL-1RI/
mice, we determined that IL-1RI mediates the early effect of
IL-1a on Th1 induction. However, IL-1 also promoted Th2
expansion in already established infections. We propose that
IL-1a plays distinctly different roles in the induction and
maintenance of protective immunity in murine cutaneous
leishmaniasis.
RESULTS
IL-1a mediates efficient Th1 priming only when administered
during T-cell priming
Previously, we demonstrated that administration of IL-1a
during the first 3 days after cutaneous infection of BALB/c
mice with 2 105 of L. major led to efficient Th1 priming and
protected from progressive disease (von Stebut et al., 2003).
In physiological low-dose infections, IL-1a treatment was
only effective when administered later (days 10–14 after
infection) coincident with the time of T-cell priming in this
model (von Stebut et al., 2003).
The experiments using high- and low-dose infections
suggested that the timing of IL-1a administration was critical.
In the present study, we thus tested additional IL-1a treatment
regimens (Figure 1). BALB/c mice were infected with standard
high-dose inocula on day 0. IL-1a was administered: (1) on
days 1–3 post-infection (von Stebut et al., 2003), (2) starting
after 1 week on days 7, 10, 14, 17, and 21 post-infection, or
(3) on days 1, 2, 3, 7, 10, 14, 17, and 21. As shown in
Figure 1, administration of IL-1a on days 1–3 post-infection
was most effective in mediating protection against progres-
sive disease compared to phosphate-buffered saline (PBS)-
treated controls. Mice receiving additional treatment with
IL-1a in the following 2 weeks were better protected than PBS
controls, but their lesions were larger than those in mice
treated with IL-1a on days 1–3 only. BALB/c mice receiving
IL-1a from week 1 until week 3 showed slightly enhanced
lesion progression compared to PBS-treated controls.
Next we determined whether the differences in disease
progression observed between the IL-1 treatment regimens
were associated with altered cytokine patterns. The Th
profiles in restimulated lymph nodes (LN) cells obtained
from infected mice were assessed 3 weeks post-infection
(Figure 2a–d). As expected (von Stebut et al., 2003), IFN-g
levels were significantly higher in BALB/c mice treated with
IL-1a during days 1–3, whereas the production of IL-4 (and
IL-10) was significantly decreased. Thus, the IFNg/IL-4 ratio in
BALB/c mice treated with IL-1a during T-cell priming was
clearly skewed toward Th1 early after infection (18.773.2
compared to 9.572.2 in PBS controls, Pp0.05, nX4). In
contrast, the cytokine profile of mice treated with IL-1a
during weeks 2 and 3 post-infection was not altered
compared to control BALB/c mice (IFNg/IL-4: 10.873.6).
Finally, the cytokine levels in BALB/c mice treated with IL-1a
both early (days 1–3) and late (weeks 2 and 3) post-infection
were also significantly altered towards Th1. IFNg levels were
significantly higher in LN cultures of IL-1a-treated mice as
compared to controls, and IL-4 and IL-10 were also increased
(IFNg/IL-4: 18.372.5, Pp0.05, nX4).
The decreased lesion sizes in BALB/c mice treated with
IL-1a during days 1–3 post-infection correlated with signifi-
cantly lower parasite burdens in infected ears (Figure 2e) and
spleens (Figure 2f) at week 3 post-infection. Mice treated with
IL-1a during weeks 2 and 3 post-infection did not exhibit
altered parasite loads compared to PBS-treated control
BALB/c mice.
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Figure 1. Treatment of Leishmania-susceptible BALB/c mice with IL-1a
promotes Th1-development only when administered during T-cell priming.
Groups of 45 mice of BALB/c mice were infected intradermally with 2 105
metacyclic promastigotes of L. major. Mice were treated with 50 ng IL-1a or
PBS as indicated (days 1–3 and/or from week 1 on every 3 days until week 3).
Lesion development was monitored over the course of several weeks in
three dimensions and expressed as mean7SEM. Pooled data from three
independent experiments is shown (nX18). Statistical differences between
treatment groups are depicted in the table (*Po0.05, **Po0.005,
***Po0.002).
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Similar results were obtained using Leishmania-resistant
C57BL/6 mice (Figure 3). Mice that were infected with
2105 parasites and treated with IL-1a during days 1–3
developed smaller lesions and healed within 6 weeks
independent of further treatment later on during the course
of disease. In contrast, prolonged treatment of C57BL/6 mice
with IL-1a during weeks 2 and 3 only did not significantly
alter disease outcome. In C57BL/6 mice, lesions in both PBS-
treated controls as well as mice treated with IL-1a during
weeks 2 and 3 peaked in week 5 and healed within 3 months
post-infection. Interestingly, in contrast to BALB/c mice (von
Stebut et al., 2003), in low-dose infections of C57BL/6 mice
additional treatment with IL-1a during T-cell priming (days
11–14) did not improve disease outcome (data not shown).
Perhaps the amount of IL-1 produced by C57BL/6 DC is
sufficient to facilitate optimal Th1 priming in low-dose
infections.
In aggregate, these data suggest that the time of IL-1a
administration is critical in this model. In BALB/c as well as
C57BL/6 mice, early administration of IL-1a during T-cell
priming promotes Th1-dependent disease resistance, whereas
later in infections IL-1a induces enhanced Th2-associated
lesion progression.
IL-1a-mediated protection requires signaling through IL-1
receptor type I
IL-1a and IL-1b bind to IL-1 receptor type I (IL-1RI) and
IL-1RII. Recently, five additional receptors belonging to the
IL-1R family have been characterized (Sims et al., 2001;
Subramaniam et al., 2004). Most of the proinflammatory
effects of IL-1 have been attributed to IL-1RI signaling
(Glaccum et al., 1997; Labow et al., 1997). We investigated
the involvement of IL-1RI-mediated signaling associated with
IL-1a treatment in cutaneous leishmaniasis using IL-1RI/
mice (Glaccum et al., 1997). A previous study showed no
phenotype of IL-1RI/ mice (C57BL/6129/Sv background)
in high-dose L. major infections (Satoskar et al., 1998).
However, the defect in IL-1a (and IL-1b) production by
activated DC was detected primarily in BALB/c mice and
IL-1a treatment was most efficacious in BALB/c mice (von
Stebut et al., 2003). Thus, IL-1RI-deficient mice on a BALB/c
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Figure 2. Increased Th1 development and decreased parasite burdens of
IL-1a-treated Leishmania-susceptible BALB/c mice. BALB/c mice were
infected with 2 105 L. major promastigotes. (a) Before killing, lesion
volumes were assessed in week 3 post-infection. (b–d) Antigen-specific
cytokine profiles of LN cells were determined by ELISA in week 3 and
expressed as mean7SEM. (e and f) Parasite burdens in infected ears and
spleens were determined using limiting dilution assays at week 3. Each data
point represents the number of organisms in one ear. One of two independent
experiments with similar results is shown (*Po0.05, **Po0.005, ***Po0.002
compared to PBS-treated controls).
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Figure 3. Early administration of IL-1a attenuates lesions in resistant
C57BL/6 mice. Groups of X5 C57BL/6 mice were infected intradermally
with 2 105 metacyclic promastigotes of L. major. Mice were treated with
50 ng IL-1a or PBS as indicated (compare Figure 1). Lesion volumes were
assessed every week and calculated as ellipsoids (mean7SEM, *Po0.05,
**Po0.005, ***Po0.002 compared to PBS-treated controls).
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background would be desirable for further analysis. As IL-
1RI/ mice are only available on a Leishmania-resistant
C57BL/6 background (Glaccum et al., 1997) and IL-1a
applied intradermally on days 1–3 post-infection also
promoted enhanced protection against cutaneous leishma-
niasis in high-dose-infected C57BL/6 mice (Figure 3 and von
Stebut et al., 2003), we studied C57BL/6 IL-1RI/ mice.
Groups of five wild-type C57BL/6 or IL-1RI/ mice were
infected with 2105 metacyclic promastigotes and treated
locally with 50 ng IL-1a (or 10 ml PBS) on days 1–3 post-
infection (Figure 4a and b). As expected, C57BL/6 mice
treated with cytokine exhibited smaller lesion volumes at
various time points. In contrast, IL-1RI/ mice did not
benefit from treatment with IL-1a, indicating that the IL-1a-
mediated effects require signaling through its type I receptor.
IL-1RI-deficient mice show enhanced protection and
Th1-dominant anti-Leishmania immunity
A prior study indicated that IL-1RI/ mice on a mixed
C57BL/6129/Sv background had no obvious phenotype
with regard to lesion sizes, but they showed altered Th
responses after infection with standard high doses of L. major
(Satoskar et al., 1998). In our hands and using standard high
dose inocula of L. major, C57BL/6 IL-1RI/ mice developed
somewhat smaller lesions compared to control C57BL/6 mice
(Figure 4a and b). This prompted us to investigate the
phenotype of IL-1RI/ mice in cutaneous leishmaniasis in
more detail. IL-1RI/ and C57BL/6 control mice were
infected with either standard high-dose (2 105) or physio-
logically relevant low-dose inocula (103) of L. major
(Figure 5). Especially at early time points (until week 4
post-infection), lesions of high-dose-infected IL-1RI/ mice
were significantly smaller (Figure 5a). This difference was not
obvious later in infections. In low-dose infections, ear lesions
in IL-1RI/ mice were smaller than those in wild-type ears
for the initial B2 months after infection (Pp0.002). Lesional
parasite loads were also smaller in IL-1RI/ mice, especially
in low-dose infections (Pp0.05, Figure 5b). However,
0
5
10
15
20
25
30
0 1 2 3 4 5 6 7 8 9 10 11 12
Le
si
on
 v
ol
um
e 
(m
m3
)
PBS
IL-1
∗∗∗∗
∗∗∗
∗∗∗
∗∗
C57BL/6
IL-1
IL-1
0
5
10
15
20
25
30
Le
si
on
 v
ol
um
e 
(m
m3
)
∗
∗
IL-1RI–/–
Weeks
0 1 2 3 4 5 6 7 8 9 10 11 12
a
b
Figure 4. IL-1RI signaling is responsible for mediating the protective effect
of IL-1a treatment. Groups ofX5 mice of C57BL/6 (a) or IL-1RI/ (b) mouse
ears were infected with 2105 metacyclic promastigotes of L. major into ear
skin and lesion development was assessed weekly in three dimensions
(mean7SEM). Infected mice were treated locally with 50 ng IL-1a or PBS on
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representative of three experiments with similar results.
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Figure 5. Decreased lesion volumes in IL-1RI/ mice infected with L. major
are associated with enhanced Th1 immunity. (a) Groups of X5 mice of
C57BL/6 or IL-1RI/ mice were infected with 2 105 (left panels) or 103
(right panels) metacyclic promastigotes of L. major and lesion development
was assessed weekly (mean7SEM). (b) Numbers of lesional parasites were
estimated using limiting dilution assays at 3 or 6 weeks post-infection. Mean
parasite loads are shown as bars; individual parasite counts/ear as circles.
(c) Cytokine profiles of lymph node cells from 3- and 6-week-infected mice
were determined after antigen-specific restimulation in vitro. Cytokine release
was analyzed after 48 hours by ELISA. Numbers below bars represent IFN-g/
IL-4 ratios (mean7SEM). (a–c) Pooled data fromX2 independent experiments
are shown (*Pp0.05, ***Pp0.002 compared to wild-type controls).
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cutaneous lesions in both IL-1RI/ and C57BL/6 mice
resolved within 3 months post-infection.
We also assessed the cytokine response at different time
points (Figure 5c). IFN-g and IL-4 levels were determined after
48 hours of antigen-specific restimulation of draining lymph
node cells with soluble Leishmania lysates (SLA, 25 mg/ml). In
both high- and low-dose infections, the cytokine profiles
showed stronger Th1 predominance in IL-1RI/ mice as
compared to C57BL/6 mice. This effect was most pronounced
in low-dose infections at week 6 as manifested by signifi-
cantly increased IFN-g/Il-4 ratios (1,3397598 in IL-1RI/ vs
175753 in C57BL/6 mice, n¼2, Po0.002). Thus, IL-1RI-
deficient mice showed enhanced protective immunity against
infection with L. major associated with increased Th1
development.
IL-1RI is expressed by both naive CD62Lþ as well as
Th2-differentiated CD4þ T cells
Previous results suggested that IL-1 might act on naive Th
cells to drive efficient Th1 generation (Figures 1–3 and
Shibuya et al., 1998; Filippi et al., 2003; von Stebut et al.,
2003) as well as to drive Th2 expansion in vitro (Greenbaum
et al., 1988; Lichtman et al., 1988; Shibuya et al., 1998). To
our knowledge, IL-1RI expression by various Th populations
in vivo has not been studied. As shown in Figure 6, we
detected surface expression of IL-1RI on naive CD62Lþ /
CD4þ T cells in both C57BL/6 as well as BALB/c mice using
flow cytometry. In 4 week-established L. major infections,
2-fold increased numbers of IL-1RI reactive effector (CD44þ )
CD4þ T cells were found in BALB/c mice as compared to
C57BL/6 CD4þ cells. However, protein levels of IL-1RI on
cell surfaces are very low (as few as 10 receptors/primary cell)
making quantification of receptor levels difficult (Sims and
Dower, 1994; Dinarello, 1996). In support of our finding,
several prior studies using Th1 and Th2 cell lines found
expression of IL-1RI (p80) and signaling only in Th2, but not
Th1 cells (Germann et al., 1990; Lacey and Erdmann, 1990;
Solari et al., 1990).
Even though the numbers of IL-1RIþ cells detected by
FACS are probably an underestimate of the real number of
IL-1RI-expressing cells, we attempted to enrich for CD4þ /IL-
1RIþ and CD4þ /IL-1RI cells from naive or L. major-infected
BALB/c mice using high-speed cell sorting (FACS Aria Cell
Sorting System, Becton Dickinson, Heidelberg, Germany).
Subsequently, cells were plated at 4 105/200 ml and
restimulated for 24 hours with plate-bound anti-CD3/anti-
CD28 (10 mg/ml, 3 hours, 371C). The cytokine profile (IFNg,
IL-4) in supernatants was determined by ELISA. Naive IL-
1RIþ T cells showed a balanced cytokine profile, but were
more prone towards Th1 as compared to IL-1RI cells (IFNg/
IL-4 ratio 1.7 vs 0.3, respectively). In contrast, CD4þ /IL-1RIþ
cells from L. major-infected BALB/c mice produced notice-
ably more IL-4 than CD4þ /IL-1RI cells (4,106 vs 882 pg/ml,
IFNg/IL-4 ratio: 2.2 vs 9.6). This experiment has been
repeated twice with similar results. Thus, CD4þ /IL-1RIþ
cells isolated from L. major-infected BALB/c mice appear to
represent Th2 cells, whereas IL-1RIþ Th0 cells displayed a
balanced cytokine profile.
DISCUSSION
IL-1a and IL-1b are pleiotropic cytokines that are involved in
the regulation of both innate and adaptive immunity. IL-1 is
an important inflammatory mediator that can augment the
activation of B cells, T cells (Sims and Dower, 1994;
Dinarello, 1996) and DC (Jakob and Udey, 1998; Cumber-
batch et al., 2002), and regulate cellular infiltration respon-
sible for granuloma formation (Curry and Kaye, 1992). In
cutaneous leishmaniasis, previous data suggested that DC-
derived IL-1a/b might act primarily on T cells and influence
T-cell differentiation. First, IL-1a treatment in cutaneous
leishmaniasis involved systemic rather than local effects,
since cytokine treatment at a site distant from the infection
promoted protection (Figures 1 and 2 and von Stebut et al.,
2003). Second, administration of IL-1a required specific
timing in that optimal influences on Th1 education were
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observed only if the cytokine was applied at the time of T-cell
priming (von Stebut et al., 2003). Third, prior in vitro data
indicated that isolated naive BALB/c CD4þ T cells required
IL-1a (and tumor necrosis factor-a) in addition to IL-12 to
efficiently differentiate into Th1 cells (Shibuya et al., 1998).
In this study, we confirmed that the relationship between
timing of IL-1a administration and induction of Th1 immunity
is critical. Early on during T-cell priming, IL-1a induced Th1
immunity whereas at later time points, especially in BALB/c
mice and in already established Th2 responses, IL-1a
administration was detrimental. Two IL-1 receptors (IL-1RI
and IL-1RII) have been known for some time, but additional
members of the IL-1R family have recently been character-
ized (Sims et al., 2001). Studies using IL-1RI/ mice as well
as anti-IL-1RI mAb demonstrated that many of the biologic
responses to IL-1 in vitro and in vivo are the result of IL-1RI
signaling, whereas IL-1RII serves as a decoy or scavenger
receptor. However, anti-IL-1RI treatment has not always
completely blocked the actions of IL-1 (Sims and Dower,
1994; Labow et al., 1997), suggesting that additional
receptors might mediate IL-1 effects in vivo. In this study,
we demonstrate that the effect of IL-1a during T-cell priming
in the course of experimental cutaneous leishmaniasis is
dependent on IL-1RI.
Administration of IL-1 during T-cell priming in this disease
model enhanced Th1 immunity. If IL-1a was administered
later, disease progression was enhanced, suggesting that at
this stage IL-1 promoted Th2 expansion. The differential
effects of IL-1a administration at different times during
evolving and established L. major infections suggested that
IL-1a might act on both naive as well as differentiated Th
cells. FACS analyses were performed to determine which Th
populations expressed IL-1RI. Our data indicated that Th0
cells from both mouse strains used expressed IL-1RI. In
addition, we identified more IL-1RI-expressing effector Th
cells in established infections of BALB/c mice (Th2 pre-
dominant) than in C57BL/6 mice (Th1 predominant). This
data is in line with results of earlier studies showing that
already committed Th1 clones did not respond to IL-1a
stimulation due to downregulation of IL-1RI (Greenbaum
et al., 1988; Lichtman et al., 1988; Germann et al., 1990;
Lacey and Erdmann, 1990; Solari et al., 1990; Shibuya et al.,
1998). In addition, administration of IL-1 during weeks 2 and
3 post-infection in C57BL/6 mice (Figure 2) had no effect on
already established Th1 immunity and did not speed lesion
resolution. In contrast, prior functional studies revealed that
IL-1 induced proliferation of Th2 cells both in vivo (Theodos
et al., 1994; Ajdary et al., 1997) and in vitro (Greenbaum
et al., 1988; Lichtman et al., 1988; Huber et al., 1998;
Shibuya et al., 1998) by increasing their responsiveness to
IL-4 or by serving as a costimulatory signal. Interestingly,
several groups including ours have previously demonstrated
that IL-1a synthesis by L. major-infected macrophages is
downmodulated by Th1-derived IFN-g (Cillari et al., 1989;
Wagner et al., 1991; von Stebut et al., 2003). Thus, in
cutaneous leishmaniasis the efficient generation of Th1 cells
may negatively regulate Th2 expansion by suppressing the
release of an important Th2 growth factor.
Studies examining the role of IL-1 in infection models in
which cure is associated with Th1 immunity have provided
conflicting results. On one hand, early administration of
IL-1a/b promoted resistance in infections with Trichinella
gondii and Trichinella spiralis (Pond et al., 1992; Hunter
et al., 1995). In line with our results, late administration of
IL-1 in infections with T. spiralis did not alter disease
outcome. On the other hand, improved disease outcome
was observed in anti-IL-1RI-treated C57BL/6 and BALB/c
mice infected with L. major (Theodos et al., 1994). Two
different lines of IL-1RI/ mice have been independently
generated and analyzed in infectious diseases (Glaccum
et al., 1997; Labow et al., 1997). IL-1RI/ C57BL/6 129/Sv
F2 mice were reported to be highly susceptible to infection
with L. monocytogenes (Labow et al., 1997). The same mice
showed no phenotype in infections with L. major (Satoskar
et al., 1998) and IFN-g levels were normal. However,
increased levels of IL-4 as well as 2-log increased parasite
burdens at later times post-infection (week 9–10) were
reported, indicating that these mice display slightly enhanced
Th2-like responses. In contrast, IL-1RI/ C57BL/6 mice
(backcrossed 5 generations) and wild-type mice were equally
resistant to infection with L. monocytogenes (Glaccum et al.,
1997). The latter mice were more susceptible to pulmonary
tuberculosis associated with defective granuloma formation
and decreased IFN-g production (Juffermans et al., 2000).
Disease models dependent on Th2 development have
also been studied. Both IL-1a- and IL-1b-deficient mice were
more susceptible to chronic Trichinella muris infection
displaying defective Th2 development (Helmby and Grencis,
2004). In addition, in a model of mild asthma and after
keyhole limpet hemocyanin-immunization, attenuated Th2
responses were observed (Satoskar et al., 1998; Schmitz
et al., 2003).
Using C57BL/6 IL-1RI/ mice, we found enhanced
development of Th1-predominant immunity with reduced
lesion sizes, decreased lesional parasite loads and cytokine
profiles that were additionally skewed toward Th1 in
response to L. major infection as compared to profiles in
control C57BL/6 mice. These effects were most prominent in
infections using the physiologically more relevant low-dose
inoculae mimicking those occurring during natural transmis-
sions (Belkaid et al., 2000). In contrast to infections with
supra-physiologically high doses of L. major, in the low-dose
model, Th1 education (early on after infection) and Th2
expansion (later on) occur at different time points. In IL-1RI/
mice, the two opposing Th-regulating roles of IL-1 cannot
be observed. We suggest that the apparent increased
resistance of these mice reflects the dominant effect of
attenuated IL-1-dependent expansion of Th2 cells, which is
transiently observed even in Leishmania-resistant wild-type
C57BL/6 mice (Sacks and Noben-Trauth, 2002). Our findings
are in line with the demonstration that continuous adminis-
tration of anti-IL-1RI antibodies to either resistant or
susceptible mice attenuated lesion development (Theodos
et al., 1994). The parasite burdens and cytokine profiles were
not dramatically changed which may have been due to the
utilization of supra-physiologic high-dose inocula. However,
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in anti-IL-1RI-treated C57BL/6 mice, antigen-specific IFNg
release was increased as compared to untreated mice.
IL-1RI, IL-18R, and Toll-like receptors use overlapping
signaling pathways that include the adaptor molecule
myeloid differentiation marker 88. Genetically resistant
myeloid differentiation marker 88/ mice are reportedly
highly susceptible to L. major infection and mounted Th2
responses (Muraille et al., 2003) compared to IL-1RI- or IL-
18-deficient mice, which both mounted protective immunity
(Satoskar et al., 1998; Monteforte et al., 2000). These data
suggest that receptors other than IL-1RI, for example various
Toll-like receptors, are critically important for induction of
protective Th1-immunity against Leishmania in mice.
Our data suggest that IL-1 engages different Th subpopula-
tions at different times after initiation of L. major infections in
mice. Expression of IL-1RI by various Th populations may be
responsible for the differences in disease outcome. Early on,
proinflammatory IL-1a released by infected DC participates
in the efficient induction of Th1 cells from naive Th0 cells via
IL-1RI. In established infections, IL-1RI-mediated signaling
promotes the expansion of Th2 cells and disease progression.
Therefore, the coordinated regulation of IL-1a/b production
and action may influence the intensity and quality of immune
responses that ensue. Genetically determined differences that
relate to IL-1 production or action may contribute signifi-
cantly to disease outcome.
MATERIALS AND METHODS
Mice
BALB/c mice or animals (8–12 weeks old) deficient for IL-1RI
(Glaccum et al., 1997) and their corresponding wild-type control
C57BL/6 mice were bred and housed under specific pathogen-free
conditions in the Animal Care Facility in Mainz. Animal experi-
mentation was conducted in accordance with current federal
guidelines.
Parasites and infections
Metacyclic promastigotes of L. major clone VI (MHOM/IL/80/
Friedlin) were prepared as described previously (von Stebut et al.,
2003). Groups of five mice were infected with standard high-dose
(2 105) or low-dose (103) inocula by injection of infectious stage
metacyclic promastigotes into ear skin (Belkaid et al., 2000). In some
experiments, mice were treated locally with 50 ng IL-1a (Peprotech,
Tebu, Berlin, Germany) or PBS (10 ml) on the days indicated. Lesion
volumes were measured weekly in three dimensions and are
reported as ellipsoids ((a/2 b/2 c/2) 4/3p). Organisms present
in lesional tissue were enumerated using a limiting dilution assay
in Schneider’s Drosophila media (BioWhittaker, Taufkirchen,
Germany), 2% human urine, 10% fetal calf serum, 2% glutamine,
1% penicillin/streptomycin, and 0.5% 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid as described (von Stebut et al., 2003).
Cytokine profiles of infected mice
For measurement of antigen-specific cytokine production, retro-
auricular LN were recovered and single-cell suspensions were
prepared every other week after L. major infection. Cells were added
to 96-well plates in the presence of 25 mg/ml soluble L. major lysate
(von Stebut et al., 2003) (at 106 LN cells/200 ml) in Roswell Park
Memorial Institute (RPMI)/5% fetal calf serum. Culture supernatants
were assayed for the presence of IFN-g (R&D Systems, Du¨sseldorf,
Germany, detection limit 15.6 pg/ml) and IL-4 (BD Biosciences,
Heidelburg, Germany, detection limit 7.8 pg/ml) after 48 hours using
ELISA.
Flow cytometry
To determine IL-1RI expression, cells from draining LN and spleens
were recovered from naive and 4-week L. major-infected BALB/c
and C57BL/6 mice. Single-cell suspensions were prepared and
stained with anti-IL-1RI (12A6), biotinylated anti-rat IgG and
Streptavidin-PE (0.1 mg/10ml/2 105 cells). Subsequently, all cells
were stained with anti-CD4 conjugated to PE-Cy5 (clone L3T4) and
anti-CD62L or anti-CD44 (FITC conjugated, all from Becton
Dickinson, Heidelberg, Germany) or appropriate isotype. Cells were
analyzed using a FACScan flow cytometer equipped with CellQuest
software (Becton Dickinson, Heidelberg, Germany).
Statistics
Statistical analysis was performed using the Wilcoxon signed-rank
test for non-parametric measurements.
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